Join Cyagen and UH Mānoa for an exclusive Lunch & Learn seminar on the next generation of genetically engineered mouse models.

Discover how cutting-edge technologies—such as ES-cell homologous recombination, CRISPR-mediated editing, and full-length humanization of mouse genes—are revolutionizing preclinical research across oncology, immunology, neuroscience, and rare genetic diseases. Whether you are developing novel therapies or modeling complex human diseases, this seminar will provide critical insights into accelerating your research with high-precision animal models.

Seats are limited—register now to secure your complimentary lunch and connect directly with Cyagen's leading scientific experts!

Seminar Details

Where: The University of Hawaiʻi at Mānoa - Human Nutrition, Food and Animal Sciences (HNFAS) Department

AgSci Bldg, Room 216

1955 East-West Rd., Honolulu, HI 96822

Date: May 8, 2025

Time: 12 PM - 2 PM (HST)

Complimentary lunch & light refreshments provided for registered attendees

Can't make it in-person? Join us on Zoom! 

Meeting ID: 861 2554 2638 Click to Join the Zoom Livestream >> 

Presentation Details

The development of sophisticated genetically engineered mouse models is essential—but often challenging—for advancing biomedical research. Dr. Marvin Yingbin Ouyang, Executive Vice President and Chief Scientific Officer at Cyagen, will lead a detailed session covering:

• Traditional and Modern Methods: Overview of ES-cell based homologous recombination and CRISPR/Cas9-mediated genome editing strategies.
  
• Cyagen’s Ready-to-Use Mouse Models: Introduction to Cyagen’s extensive library of knockout (KO) and conditional knockout (cKO) models.
  
• TurboKnockout™ Platform: An exclusive look at Cyagen’s TurboKnockout™ technology, which accelerates generation timelines for complex mouse models by 4–6 months compared to conventional approaches.
  
• HUGO-GT™ and HUGO-Ab™ Humanized Mouse Models: Discover how complete human gene replacements (exons, introns, UTRs) provide more clinically relevant models for cancer research, immunology, and gene therapy development.
  

Who Should Attend?   

• Researchers in oncology, immunology, and neuroscience
• Scientists using animal models of human disease
• Pre-/Clinical researchers focused on gene therapy drug development
• Geneticists interested in rare diseases
• Students in biomedical fields

Meet Our Experts   

Dr. Marvin Yingbin Ouyang, Executive Vice President and Chief Scientific Officer, and Dr. Joseph Wekselblatt, Senior Scientific Business Development Manager, will represent Cyagen at IMMUNOLOGY2025™ Booth 430. While in town, they will be visiting UH Mānoa to provide an exclusive seminar for local researchers about Cyagen’s genomically humanized mouse model programs – HUGO-GT™ and HUGO-Ab™ – in which the mouse gene is replaced with the full-length human gene, including exons, introns, and untranslated regions (UTRs).

They are eager to discuss how Cyagen’s comprehensive, next-generation CAM & CRO services can accelerate your R&D efforts.

Presenter: Marvin Yingbin Ouyang, MD, PhD

Cyagen’s Executive Vice President and Chief Scientific Officer

Before joining Cyagen in 2012, Dr. Ouyang served as a senior scientist at Oklahoma Medical Research Foundation, Thios Pharmaceuticals in the United States, and as Group Leader of the Molecular Biology Department of Taconic Biosciences. Over the past 20 years, he has committed himself to the custom design and generation of genetically engineered mice. While at Cyagen, he has successfully developed thousands of transgenic and gene knockout/knockin mouse and rat models for the biomedical research and drug discovery communities worldwide. He has published many papers in high-level academic journals such as PNAS and JBC; his technical services have been directly cited by Nature and other international journals hundreds of times.

Joseph (Joe) Wekselblatt, PhD

Senior Scientific Business Development Manager at Cyagen

Dr. Joseph (Joe) Wekselblatt has been in the scientific field for well over a decade, having studied the visual capabilities in species including mice and rats, barn owls, tree shrews, humans and non-human primates. Dr. Wekselblatt attended Brown University from 2004 to 2008, where he earned a Bachelor's degree in Cognitive Science. Joseph then attended the University of Oregon from 2011 to 2017, where he earned a Doctor of Philosophy in Neurobiology. Joseph is currently a Postdoctoral Researcher at Caltech, where he has been since 2017. In 2023, he transitioned to Cyagen as a Senior Scientific Business Development Manager.

Dr. Wekselblatt's research focuses on understanding visual object representation in the tree shrew brain, using advanced imaging and manipulation techniques. He uses tree shrews as a model due to their complex visual system, which bridges the gap between rodents and primates. His work involves mapping the brain-wide organization of the visual system using functional ultrasound, measuring local activity with silicon probes, and manipulating genetically defined cells with targeted virus delivery. He also studies the behavioral effects of these manipulations, aiming to provide insights into sensory transformations in cortical networks.

Request a Free Project Consultation

Dr. Ouyang and Dr. Wekselblatt will also be available for individual consultations during their visit to Honolulu for IMMUNOLOGY2025™ May 3-7. If you would like to schedule a free one-on-one meeting to discuss your project needs—including CAM, CGT, and preclinical development—please click here to book your consultation!

If you are interested in scheduling a free consultation on your CAM/CGT projects outside of the event, please Contact Us.  

Founded in 2006, Cyagen is a global provider of genetically modified rodent models and innovative cell and gene therapy (CGT) solutions for research and development (R&D), including: disease model development, AAV discovery, drug efficacy studies, and more. The company has established extensive collaborations with scientists and institutions in more than 100 countries, leading to the publication of over 6,300 academic articles, many of which were in the three major journals of CNS (Cell, Nature, Science). From its robust foundation in animal model development, to implementation of artificial intelligence (AI)-powered tools for data analysis and therapeutic discoveries, Cyagen provides one-stop solutions for accelerating basic research and new drug R&D with our unique offering of models, data, algorithms, and services.